Now, the synergy between the technological capabilities of GlobalSpace and the Salesforce capabilities of InnoPharm is poised to create a value proposition for the combined client base of both entities.
GlobalSpace Technologies, a trailblazer in innovative digital pharma solutions for over a decade, has announced the signing of a Memorandum of Understanding for the acquisition of InnoPharm Healthcare Private Limited with a 51 per cent stake and share swap of an undisclosed amount. InnoPharm is a contract sales force organisation with marquee pharmaceutical companies as clients.
GlobalSpace technologies is revolutionizing healthcare through cutting-edge solutions, analytics, and AI. At the beginning of this year, the company forayed into digital therapeutics with GoRoga, a one-of-a-kind anti-stress wearable.
Now, the synergy between the technological capabilities of GlobalSpace and the Salesforce capabilities of InnoPharm is poised to create a value proposition for the combined client base of both entities. Cross-selling opportunities and operational efficiencies will drive enhanced market presence.
"At GlobalSpace Technologies, we are always focused on delivering value to our customers while addressing their evolving needs. Through this acquisition, we are solidifying our position in the DTP ( Digital - Telecalling - Physical) model.
The DTP model leveraging our digital assets DocExa and MEDIOLA has already demonstrated a 20 per cent growth for Vintage Pharma MNC brands through a pilot project. While DocExa has reached 1.18 + lac doctors, the MEDIOLA app serves 30000+ pharmacies. The merger of GlobalSpace's Digital and tele-calling strengths with Innopharm's ability to manage feet on the street amplifies the potential for GlobalSpace Technologies to elevate the Stakeholder value creation" according to Founder and CEO Krishna Singh, GlobalSpace Technologies Limited.
"This collaboration will further strengthen the positioning and open new avenues for creating enhanced value for the pharma industry. Leveraging GlobalSpace's existing technological solutions, we anticipate a positive impact on EBITDA, contributing to sustained growth and profitability of the combined enterprise" according to Agnelo D'Silva, Founder Director, Innopharm Healthcare Private Limited.